Zoetis Inc. $ZTS Shares Purchased by Copperwynd Financial LLC

Copperwynd Financial LLC raised its stake in shares of Zoetis Inc. (NYSE:ZTS) by 5.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,448 shares of the company’s stock after buying an additional 339 shares during the period. Copperwynd Financial LLC’s holdings in Zoetis were worth $1,006,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of ZTS. Nuveen LLC acquired a new position in Zoetis during the 1st quarter valued at about $616,375,000. Mackenzie Financial Corp raised its holdings in shares of Zoetis by 4,158.3% in the 1st quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company’s stock worth $300,481,000 after purchasing an additional 1,782,110 shares in the last quarter. Polen Capital Management LLC boosted its holdings in Zoetis by 17.6% during the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after buying an additional 1,313,653 shares in the last quarter. Amundi boosted its holdings in Zoetis by 30.8% during the first quarter. Amundi now owns 3,595,628 shares of the company’s stock worth $575,691,000 after buying an additional 846,909 shares in the last quarter. Finally, OVERSEA CHINESE BANKING Corp Ltd grew its position in Zoetis by 475.9% in the first quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 900,261 shares of the company’s stock worth $148,228,000 after buying an additional 743,926 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

Zoetis stock opened at $143.61 on Thursday. The firm’s 50 day simple moving average is $149.41 and its 200-day simple moving average is $154.74. The company has a market cap of $63.65 billion, a P/E ratio of 24.72, a price-to-earnings-growth ratio of 2.29 and a beta of 0.90. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. Zoetis Inc. has a fifty-two week low of $139.34 and a fifty-two week high of $196.55.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping the consensus estimate of $1.62 by $0.14. The business had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same period last year, the company posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ZTS. Leerink Partnrs lowered shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday. Piper Sandler lifted their price target on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Finally, Stifel Nicolaus lowered shares of Zoetis from a “buy” rating to a “hold” rating and decreased their price target for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Five investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, Zoetis presently has a consensus rating of “Moderate Buy” and an average target price of $200.88.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.